Eribulin Mesylate
ApprovedCompleted 0 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Breast Neoplasms
Conditions
Breast Neoplasms
Trial Timeline
Mar 28, 2018 → Jun 28, 2019
NCT ID
NCT03583944About Eribulin Mesylate
Eribulin Mesylate is a approved stage product being developed by Eisai for Breast Neoplasms. The current trial status is completed. This product is registered under clinical trial identifier NCT03583944. Target conditions include Breast Neoplasms.
What happened to similar drugs?
20 of 20 similar drugs in Breast Neoplasms were approved
Approved (20) Terminated (5) Active (0)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (19)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03441360 | Phase 2 | Completed |
| NCT03583944 | Approved | Completed |
| NCT03361436 | Phase 1 | Active |
| NCT03437083 | Pre-clinical | Completed |
| NCT03058406 | Pre-clinical | Completed |
| NCT02481050 | Phase 2 | Completed |
| NCT02338037 | Phase 1 | Completed |
| NCT02171260 | Phase 1 | Completed |
| NCT03245112 | Pre-clinical | UNKNOWN |
| NCT01961544 | Approved | Completed |
| NCT01458249 | Phase 2 | Completed |
| NCT01463891 | Pre-clinical | Completed |
| NCT01328249 | Phase 2 | Completed |
| NCT01240421 | Pre-clinical | Completed |
| NCT01268150 | Phase 2 | Completed |
| NCT01269346 | Phase 2 | Completed |
| NCT01142661 | Pre-clinical | Completed |
| NCT01106248 | Phase 1 | Completed |
| NCT00965523 | Phase 2 | Completed |
Competing Products
20 competing products in Breast Neoplasms